{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:00:16Z","timestamp":1794096016772,"version":"4.8.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.gastrohep.2021.04.011","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T21:55:05Z","timestamp":1622066105000},"page":"335-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Adherence to subcutaneous biologic treatment for inflammatory bowel disease"],"prefix":"10.1016","volume":"45","author":[{"given":"Laura","family":"Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Ramos-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel De La","family":"Barreda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Guti\u00e9rrez-Nicol\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Carrillo-Palau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Alonso-Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Nazco-Casariego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Quintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2021.04.011_bib0100","unstructured":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies [Internet]; 2018. [cited December 23]."},{"issue":"Suppl. 1","key":"10.1016\/j.gastrohep.2021.04.011_bib0105","doi-asserted-by":"crossref","first-page":"S594","DOI":"10.1093\/ecco-jcc\/jjz203.872","article-title":"Epidemiology, clinical characteristics, evolution and treatments in newly diagnosed inflammatory bowel disease (IBD): results from the nationwide EpidemIBD study of GETECCU","volume":"14","author":"Chaparro","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0110","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0115","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/j.gastro.2016.09.046","article-title":"Management strategies to improve outcomes of patients with inflammatory bowel diseases","volume":"152","author":"Colombel","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0120","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0125","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0130","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0135","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0140","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0145","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn's disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0150","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1097\/MIB.0000000000000700","article-title":"Long-term compliance with oral 5-aminosalicylic acid therapy and risk of disease recurrence in patients with ulcerative colitis: a population-based cohort study","volume":"22","author":"Prosberg","year":"2016","journal-title":"Inflam Bowel Dis"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0155","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/ajg.2017.438","article-title":"Defining an optimal adherence threshold for patients taking subcutaneous anti-TNFs for inflammatory bowel diseases","volume":"113","author":"Govani","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0160","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1097\/MIB.0b013e31828132cb","article-title":"Adherence to anti-TNF therapy in inflammatory bowel diseases: a systematic review","volume":"19","author":"Lopez","year":"2013","journal-title":"Inflam Bowel Dis"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0165","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1097\/MIB.0b013e31829ed8a6","article-title":"Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease","volume":"19","author":"Selinger","year":"2013","journal-title":"Inflam Bowel Dis"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0170","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/ibd\/izy102","article-title":"Nonadherence to biologic therapies in inflammatory bowel disease","volume":"24","author":"Wentworth","year":"2018","journal-title":"Inflam Bowel Dis"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0175","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1097\/00005650-198808000-00007","article-title":"A general method of compliance assessment using centralized pharmacy records. Description and validation","volume":"26","author":"Steiner","year":"1988","journal-title":"Med Care"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0180","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/ecco-jcc\/jjw002","article-title":"Non-adherence to anti-TNF therapy is associated with illness perceptions and clinical outcomes in outpatients with inflammatory bowel disease: results from a prospective multicentre study","volume":"10","author":"van der Have","year":"2016","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0185","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/ibd.21310","article-title":"Are your patients taking their medicine? Validation of a new adherence scale in patients with inflammatory bowel disease and comparison with physician perception of adherence","volume":"17","author":"Trindade","year":"2011","journal-title":"Inflam Bowel Dis"},{"key":"10.1016\/j.gastrohep.2021.04.011_bib0190","doi-asserted-by":"crossref","first-page":"15242","DOI":"10.1073\/pnas.1301687110","article-title":"The Hawthorne effect and energy awareness","volume":"110","author":"Schwartz","year":"2013","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570521001692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570521001692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:45:12Z","timestamp":1759322712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570521001692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0210570521001692"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2021.04.011","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence to subcutaneous biologic treatment for inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2021.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}